Adaptimmune Therapeutics plc
ADAP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $136 | $159 | $235 | $584 |
| - Cash | $91 | $144 | $108 | $150 |
| + Debt | $74 | $25 | $23 | $25 |
| Enterprise Value | $119 | $41 | $150 | $460 |
| Revenue | $178 | $60 | $27 | $6 |
| % Growth | 195.3% | 122% | 341.5% | – |
| Gross Profit | $178 | $50 | -$101 | -$105 |
| % Margin | 100% | 83.6% | -370.5% | -1,706.6% |
| EBITDA | -$53 | -$128 | -$156 | -$156 |
| % Margin | -29.6% | -212.7% | -573.1% | -2,531.8% |
| Net Income | -$71 | -$114 | -$165 | -$158 |
| % Margin | -39.8% | -188.9% | -609.5% | -2,571% |
| EPS Diluted | -0.28 | -0.57 | -1.02 | -1.02 |
| % Growth | 50.9% | 44.1% | 0% | – |
| Operating Cash Flow | -$73 | -$141 | -$142 | $11 |
| Capital Expenditures | -$3 | -$5 | -$30 | -$9 |
| Free Cash Flow | -$76 | -$146 | -$172 | $2 |